Shoklo Malaria Research Unit,
Myanmar Oxford Clinical Research Unit, Burnet Institute
 | aungpyaephyo@tropmedres.ac |
Aung Pyae Phyo, a Burmese (Myanmar) clinician, finished his medical training in 2001 in Yangon. He joined the Shoklo Malaria Research Unit in 2005 where he has led the cohort which unearthed the emergence of artemisinins resistance on the Thai-Myanmar border in 2010. Afterwards, he pursued research on the Artemisinin Combination Therapy resistant malaria as well as the trials on the new antimalarial compounds such as OZ439 (Artefenomel), KAF156 (Ganaplacide) and KAE609 (Cipargamin).
In 2017 Aung Pyae Phyo completed his Doctor of Philosophy in Clinical Medicine at Nuffield Department of Medicine, Oxford University. His Phd thesis title is “Defining the optimal management of Plasmodium falciparum malaria”.After completing the DPhil, he joined the Myanmar Oxford Clinical Research Unit in Yangon, Myanmar where his focus is malaria elimination and surveillance of the spread of drug resistant malaria in Greater Mekong Subregion (GMS). In 2019 he received post-doctoral International Training fellowship from the Wellcome Trust.
In 2017 Aung Pyae Phyo completed his Doctor of Philosophy in Clinical Medicine at Nuffield Department of Medicine, Oxford University. His Phd thesis title is “Defining the optimal management of Plasmodium falciparum malaria”.After completing the DPhil, he joined the Myanmar Oxford Clinical Research Unit in Yangon, Myanmar where his focus is malaria elimination and surveillance of the spread of drug resistant malaria in Greater Mekong Subregion (GMS). In 2019 he received post-doctoral International Training fellowship from the Wellcome Trust.
